Jiri Minarik

Author PubWeight™ 12.32^‹?›

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.	N Engl J Med	2014	5.08
2	Induction treatment of light chain deposition disease with bortezomib: rapid hematological response with persistence of renal involvement.	Leuk Lymphoma	2011	1.49
3	The relationship between proliferation and apoptosis in patients with monoclonal gammopathy of undetermined significance or multiple myeloma.	Haematologica	2005	0.80
4	Tc-99m MIBI scintigraphy in multiple myeloma: prognostic value of different Tc-99m MIBI uptake patterns.	Clin Nucl Med	2010	0.80
5	Clinical implication of centrosome amplification and expression of centrosomal functional genes in multiple myeloma.	J Transl Med	2013	0.78
6	Combination of serum microRNA-320a and microRNA-320b as a marker for Waldenström macroglobulinemia.	Am J Hematol	2015	0.77
7	Cell cycle genes co-expression in multiple myeloma and plasma cell leukemia.	Genomics	2013	0.76
8	Outcome of patients with multiple myeloma and hypertension treated with angiotensin-I-converting enzyme inhibitors during high-dose chemotherapy.	Hematol J	2005	0.76
9	The correlation of serum immunoglobulin free light chain levels and selected biological markers in multiple myeloma.	Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub	2008	0.76
10	Low-dose acyclovir prophylaxis for bortezomib-induced herpes zoster in multiple myeloma patients.	Br J Haematol	2012	0.75
11	Analysis of thymidine kinase serum levels by novel method DiviTum in multiple myeloma and monoclonal gammopathy of undetermined significance - comparison with imaging methods 99mTc-MIBI scintigraphy and 18F-FDG PET/CT.	Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub	2014	0.75
12	The relationship between some soluble osteogenic markers, angiogenic cytokines/other biological parameters and the stages of multiple myeloma evaluated according to the Durie-Salmon and International Prognostic Index stratification systems.	Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub	2009	0.75
13	Similar efficacy of thalidomide- and bortezomib-based regimens for first relapse of multiple myeloma.	Ann Hematol	2011	0.75